Use this tool to calculate the biweekly pay based on hourly, annual, or any other wage or salary.
This matching-adjusted indirect comparison (MAIC) assessed 52-week relative efficacy of bimekizumab versus secukinumab and ixekizumab. Methods: Individual patient data from BE MOBILE 2 (bimekizumab 160 mg; N = 220) were matched to pooled summary data from MEASURE 1/2/3/4 (secukinumab 150 ...
Last year DeepMind’s breakthrough AI system AlphaFold2 was recognised as a solution to the 50-year-old grand challenge of protein folding, capable of predicting the 3D structure of a protein directly from its amino acid sequence to atomic-level accuracy. This has been a watershed moment for ...
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial - ScienceDirect Bimekizumab versus ustekinumab for the treatment of moderate to...
Here we report health-related quality of life (HRQoL) outcomes (ASQoL, SF-36 and EQ-5D-3L) from the two parallel phase 3 studies up to Week (Wk)52. METHODS. BE MOBILE 1 and 2 have similar study designs: 16-Wk double-blind placebo (PBO)-controlled period followed by 36-Wk ...
Clinical data were evaluated at each follow-up visit [week (W)16-36-52]. A total of 43 patients respected the inclusion and exclusion criteria. At baseline, mean PASI and DLQI were 17.4±8.3 and 24.1±5.3, respectively. A statistically significant improvement of both scores was reported ...
Larrey D,Lohse A,de Ledinghen V,et al.4Week therapy with the non-nucleosidic polymerase inhibitor BI207127in combination with peginterferon-alfa2A and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. Journal of Hepatology . 2010...